Market for this liver drug could rival hepatitis C
July 15, 2014 at 08:06 AM EDT
NASH, or nonalcoholic steatohepatitis, is becoming more widespread, and the market for treatments for the liver disorder may rival those for hepatitis C.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.